Država: Novi Zeland
Jezik: engleski
Izvor: Medsafe (Medicines Safety Authority)
Ceftazidime pentahydrate 2.3296 g equivalent to ceftazidime 2 g (sterile);
Fresenius Kabi New Zealand Limited
2 g
Powder for injection
Active: Ceftazidime pentahydrate 2.3296 g equivalent to ceftazidime 2 g (sterile) Excipient: Sodium carbonate
Prescription
Indicated for the treatment of adults and children including neonates with single or multiple infections caused by susceptible organisms. May be used alone as first choice medicine before the results of sensitivity tests are available. May be used in combination with an aminoglycoside or most other beta-lactam antibiotics. May be used with an antibiotic against anaerobes when the presence of Bacteroides fragilis is suspected. Susceptibility to ceftazidime will vary with geography and time and local susceptibility data should be consulted where available (see section 5.1 Pharmacodynamic properties). Indications include: - Severe infections e.g. - septicaemia, bacteraemia, peritonitis, meningitis. - infections in immunosuppressed patients. - infections in patients in intensive care, e.g. infected burns. - Respiratory tract infections including lung infections in cystic fibrosis. - Ear, nose and throat infections. - Urinary tract infections. - Skin and soft tissue infections. - Gastrointestinal, biliary and abdominal infections. - Bone and joint infections. - Infections associated with haemo- and peritoneal dialysis and with continuous ambulatory peritoneal dialysis (CAPD).
Package - Contents - Shelf Life: Vial, glass, Type II clear with with halobutyl rubber stopper and flip-off cap - 1 dose units - 36 months from date of manufacture stored at or below 25°C - Vial, glass, Type II clear with with halobutyl rubber stopper and flip-off cap - 5 dose units - 36 months from date of manufacture stored at or below 25°C - Vial, glass, Type II clear with with halobutyl rubber stopper and flip-off cap - 10 dose units - 36 months from date of manufacture stored at or below 25°C
2018-05-10
1 NEW ZEALAND DATA SHEET 1. PRODUCT NAME CEFTAZIDIME KABI ceftazidime (as pentahydrate) 1 g or 2 g powder for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION CEFTAZIDIME KABI powder for injection contains either 1 g or 2 g of ceftazidime (as pentahydrate). For the full list of excipients, see section 6.1 List of excipients. 3. PHARMACEUTICAL FORM Powder for injection. Supplied as a white to pale yellow powder. On the addition of Water for Injections, Ceftazidime Kabi dissolves with effervescence to produce a solution for injection. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS CEFTAZIDIME KABI is indicated for the treatment of adults and children including neonates with single or multiple infections caused by susceptible organisms. May be used alone as first choice medicine before the results of sensitivity tests are available. May be used in combination with an aminoglycoside or most other beta-lactam antibiotics. May be used with an antibiotic against anaerobes when the presence of _Bacteroides _ _fragilis _is suspected. Susceptibility to ceftazidime will vary with geography and time and local susceptibility data should be consulted where available (see section 5.1 Pharmacodynamic properties). Indications include: - Severe infections e.g. -septicaemia, bacteraemia, peritonitis, meningitis. -infections in immunosuppressed patients. -infections in patients in intensive care, e.g. infected burns. - Respiratory tract infections including lung infections in cystic fibrosis. - Ear, nose and throat infections. - Urinary tract infections. 2 - Skin and soft tissue infections. - Gastrointestinal, biliary and abdominal infections. - Bone and joint infections. - Infections associated with haemo- and peritoneal dialysis and with continuous ambulatory peritoneal dialysis (CAPD). 4.2 DOSE AND METHOD OF ADMINISTRATION Dose Dosage depends upon the severity, sensitivity, site and type of infection and upon the age and renal function of the patient. ADULTS: 1-6 g/day in 2 or 3 divided doses by intravenous (i.v.) or in Pročitajte cijeli dokument